A pharmacovigilance analysis found disproportionately higher reports of vascular ectasia and regional bleeding with sotatercept compared with other pulmonary arterial hypertension (PAH) drugs. The findings highlight a signal that may affect clinical monitoring strategies for PAH patients already balancing thromboembolic risk, bleeding concerns, and complex long-term treatment regimens. While pharmacovigilance studies are not controlled efficacy trials, they can meaningfully inform label interpretation and post-market surveillance priorities. Clinicians will likely focus on which patient subsets show higher susceptibility and how to manage adverse events if these reports translate into higher real-world incidence rates.
Get the Daily Brief